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Summary
Clinical trials are reviewed, involving proteins and peptides derived from milk (predomi-
nantly bovine), with the exception of lactoferrin, which will be the subject of another ar-
ticle. The most explored milk fraction is α-lactalbumin (LA), which is often applied with 
glycomacropeptide (GMP) – a casein degradation product. These milk constituents are used 
in health-promoting infant and adult formulae as well as in a modified form (HAMLET) to 
treat cancer. Lactoperoxidase (LCP) is used as an additive to mouth hygiene products and as 
a salivary substitute. Casein derivatives are applied, in addition, in the dry mouth syndrome. 
On the other hand, casein hydrolysates, containing active tripeptides, found application 
in hypertension and in type 2 diabetes. Lysozyme is routinely used for food conservation 
and in pharmaceutical products. It was successfully used in premature infants with con-
comitant diseases to improve health parameters. When used as prophylaxis in patients with 
scheduled surgery, it significantly reduced the incidence of hepatitis resulting from blood 
transfusion. Lysozyme was also used in infected children as an antimicrobial agent show-
ing synergistic effects in combination with different antibiotics. Proline-rich polypeptide 
(PRP) was introduced to therapy of Alzheimer’s disease patients. The therapeutic value of 
PRP was proved in several clinical trials and supported by studies on its mechanism of ac-
tion. Concentrated immunoglobulin preparations from colostrum and milk of hyperimmu-
nized cows showed efficacy in prevention of infections by bacteria, viruses and protozoa. 
A nutrition formula with milk-derived TGF-β2 (Modulen IBD®) found application in treat-
ment of pediatric Crohn’s disease. In conclusion, the preparations containing milk-derived 
products are safe and effective measures in prevention and treatment of infections as well 
as autoimmune and neoplastic diseases.
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IntroductIon
Milk is an essential diet for mammalian neonates and in-
fants. It supplies vital nutritional ingredients for normal 
development and arms the neonate with immunoglobulins, 
proteins and peptides for innate immunity. Milk ingredients 
not only contribute to resistance to pathogens but also play 
a crucial role in promoting maturation of the gastrointesti-
nal tract and immune system of the newborn (reviewed in 
[5]). Milk proteins are sometimes precursors of different 
biologically active peptides e.g. casein-derived glycoma-
cropeptide and angiotensin-I-converting enzyme peptide 
inhibitors. Milk, and in particular colostrum, also contains 
a proline-rich polypeptide of important biological activities 
and therapeutic value. These peptides can be released by en-
zymatic hydrolysis either during gastrointestinal digestion 
or during food processing [26].
Biological properties of milk-contained proteins and pep-
tides have been extensively studied in in vitro and animal 
models (reviewed in [19,44,53,91,119]). The proteins and pep-
tides were also included in clinical studies showing a benefit 
in prevention and therapy of microelement deficiencies, car-
diovascular diseases, oral cavity diseases, autoimmune and 
neoplastic diseases, inflammation, infection and recovery 
of the immune system function following chemotherapy. 
The results are very encouraging and have led to the broad 
application of milk constituents in the dairy and pharma-
ceutical industries.
The aim of this article is to review applications of the most 
important milk-derived proteins and peptides in clinical 
trials. The summary of the clinical effects of the investigated 
proteins and peptides is depicted in Table 1. Examples of bio-
active peptides (peptide name, sequence and function) deri-
ved from milk proteins are presented in Table 2. Considering 
the high number of preclinical and clinical trials on lactofer-
rin, this will be a subject of another review (in preparation).
α-lactalbumIn and glycomacropeptIde
The importance of α-lactalbumin (LA) in infant nutrition 
is obvious since this protein constitutes a large part of the 
whey and total protein in human milk. This is in contrast 
to bovine milk, where LA is only a minor part of the milk 
protein content (see Fig. 1). Nevertheless, the authors 
suggest that because of high amino acid homology (72%) 
between human and bovine LA [37], the bovine protein 
would be a valuable component of infant formulas as well 
as patients’ diet supplements. LA may be related to lyso-
zyme because of similarities in their molecular structu-
res and genetic features [71]. The protein is a component 
of lactose synthase and exhibits a number of biological 
activities, such as: ability to bind metal cations and fatty 
acids in an unfolded (apo) form, induction of apoptosis in 
tumors and immature cells, and bactericidal action by its 
peptidic fragments (reviewed in [7,37,80]). Glycomacro-
peptide (GMP) is a peptide derived from whey κ-casein 
(Table 2). It is released by chymosin and contains a high 
proportion of sialic acid, which may account for its bio-
logical activity (reviewed in [14,94]). In our study [117], 
GMP was shown to protect mice against endotoxemia and 
bacteremia with a higher efficacy than lactoferrin (pro-
tein with proved activity). LA and GMP are often used in 
a combination in nutritional preparations so therapeutic 
efficacy of these substances will be described together 
in one chapter.
LA or GMP-supplemented formulas were used in a study 
on infant Rhesus monkeys, as compared to control and 
breastfed infants, with no adverse effects on nutritional 
status [47]. Of note, GMP formula increased zinc absorp-
tion whereas LA supplementation resulted in a plasma 
amino acid pattern similar to that of breastfed monkey 
infants. Weight gain and safety of an experimental for-
mula containing LA, as compared to a control one, in 
healthy 14-day-old or younger infants, fed for 12 weeks, 
were investigated [59]. Growth and adverse events data 
supported the safety of the experimental formula, which 
was better tolerated than the control formula. An LA-
-enriched formula administered for 120 days to infants 
was tested with regard to infant growth, protein mar-
kers and biochemical parameters [104]. The LA formula 
was safe, but no significant differences in the studied 
parameters were registered as compared to infants fed a 
standard formula or human milk. In another, multicen-
tre, double-blind, randomized trial an LA-enriched and 
symbiotic-supplemented infant formula was tested for 
safety, tolerance and prevention of atopic dermatitis [84]. 
The infants fed the experimental formula exhibited less 
crying and agitation as well as less frequent manifesta-
tion of atopic dermatitis. Growth was similar in infants 
fed experimental and standard formula. Another study 
demonstrated that, compared to the standard formula-
-fed infants, the infants fed formula enriched with LA and 
GMP had weight gain similar to that of breastfed infants 
[87]. On the other hand, a study aimed at establishing an 
effect of LF and GMP-enriched formula on fecal microor-
Abbreviations: A – Ala (alanine); ACE – angiotensin-I-converting enzyme; BAMLET – bovine α-lactalbumin made 
lethal to tumor cells; CLN – Colostrinin; E – Glu (glutamic acid); F – Phe (phenylalanine); G – Gly 
(glycine); GMP – glycomacropeptide; H – His (histidine); HAMLET – human α-lactalbumin made 
lethal to tumor cells; I – Ile (isoleucine); Ig – immunoglobulins; L – Leu (leucine); LA – α-lactalbumin; 
LCP – lactoperoxidase; LF – lactoferrin; LG – β-lactoglobulin; LNAA – large neutral amino acids; 
M – Met (methionine); MFGM – milk fat globule membrane proteins; N – Asn (asparagine); –OSCN/
HOSCN – hypothiocyanate/hypothiocyanous acid; P – Pro (proline); PRP – proline-rich polypeptide; 
Q – Gln (glutamine); R – Arg (arginine); S – Ser (serine); SCN– – thiocyanate; TGF-β2 – transforming 
growth factor beta 2; V – Val (valine); W – Trp (tryptophan); Y – Tyr (tyrosine) 802
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Fig. 1.  Typical content of milk proteins in mature bovine and human milk. Shown are the major milk proteins, as well as selected additional proteins with relevance in health. The 
contents of proteins are expressed as percentage (%) of whey proteins and caseins in the total milk proteins and also whey proteins as a percentage of total whey proteins and 
caseins as a percentage of total caseins. The cited ratio of 60:40 of whey proteins to caseins in human milk is an approximation of the ratio during the normal course of lactation, 
but it varies from ~80:20 in early lactation (first days) to 50:50 in late lactation. The total protein content in breast milk is 14-16 g/L during early lactation, 8-10 g/L at 3-4 months 
of lactation and 7-8 g/L at 6 months and later [64]. The protein content in human milk is therefore 1.6-0.7% of the total milk ingredients. The protein content in bovine milk is 
34-35 g/L (3.4-3.5% of the total milk ingredients). The data adapted from [53,61,81,91,107,118]. ND – no data
ganisms in healthy infants did not reveal any differences 
as compared to breastfed infants [15]. Likewise, LA- and 
LA-GMP-enriched formula had no effect on iron absorp-
tion in healthy term infants [98]. An LA-enriched and 
probiotic supplemented infant formula was also tested 
for effects on colic [23]. Although no differences were 
found with the control group (fed standard formula) re-
garding crying duration, the researchers registered lower 
“feeding-related” gastrointestinal side-effects in infants 
fed the experimental diet. 
No significant effects of whey protein- and GMP-enriched 
diets on satiety in adults were found [56]. Likewise, no 
effects of GMP-enriched formula on cholecystokinin level 
(which may promote satiety), subjective feeling of satiety 
and food intake in 20 overweight males were found [49]. 
In a double-blind, randomized study in 127 obese volun-
teers meal replacement with GMP-enriched whey powder 
had no additional effect on the 12-month weight loss, but 
there were improvements in cardiovascular disease risk 
markers (total and LDL cholesterol, triacylglycerols, glu-803
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Table 1. Published clinical studies with milk proteins and peptides
Protein/peptide Clinical effects, number of participants References
α-Lactalbumin (LA)
Weight gain and safety (no adverse effects) in infants aged 14 days or less (n=193) [59]
Weight gain in infants fed experimental formula did not differ from the control group fed human milk (n=336) [104]
Prevention of atopic dermatitis, less crying and agitation in infants (n=97) [84]
Good weight and length gains in infants with colic, no differences in crying duration in infants, lower feeding-
related side effects (n=66)
[23]
Suppression of hunger, decreased fat balance, increased energy expenditure and protein balance (n=35) [40]
Increased loss of body fat and retention of lean muscle mass in obese subjects who drank ProlibraTM, compared to 
supplementation with an isocaloric control that had a lower calcium and lower protein content (n=106)
[28]
No effect on appetite, food intake or mood (n=18) [8]
Minimal effects on stress-induced mood (n=43) [73]
Improvement of abstract visual memory and impaired simple motor performance in depressed patients and 
healthy controls (n=43)
[12]
Higher prolactin concentration, decreased cortisol levels and reduced depressive feelings under stress in stress-
vulnerable subjects (n=58)
[69]
Advantageous effects on cognitive performance in high and low stress-vulnerable subjects (n=52) [68]
Reduced sleepiness, improved brain sustained alertness in healthy subjects; increase in plasma Trp:LNAA ratio 
(n=28)
[67]
Improved long-term memory for abstract figures in women with premenstrual complaints (n=16) [90]
Better weight gain, smaller number of rehydrations required in malnourished children with diarrhea (n=38) [25]
Equally effective in treatment of diarrhea in infants with control rehydration solution (standard glucose and 
maltodextrin plus sucrose)
[86]
HAMLET effective in reducing volume and occurrence of cutaneous papillomas (n=40) [33]
Reduction by HAMLET of bladder cancer size (n=9) [75]
Glycomacropeptide (GMP)
No significant effects on satiety in healthy adults (n=50) [56]
No effects on cholecystokinin level, subjective feeling of satiety and food intake in overweight/obese adults 
(n=20)
[49]
No additional effect on 12-mo weight loss in obese adults, but improvement in cardiovascular disease risk markers 
(n=127)
[48]
Well tolerated in phenylketonuria patients (n=15) [55]
No adverse reactions in phenylketonuria patients to GMP, decreased ureagenesis and increased plasma insulin 
as compared with a control diet, improved protein retention and phenylalanine utilization in phenylketonuria 
patients (n=11)
[106]
Significantly lower postprandial ghrelin (appetite-stimulating hormone) concentration as compared to control 
diet (n=11)
[65]
Decrease in gout flare symptoms in patients, improvements in pain and excretion of uric acid, improvement in 
tender joint count (n=120)
[18]
α-Lactalbumin (LA) + GMP
No difference in fecal microorganisms as compared to breast-fed infants (n=85) [15]
No effect on iron absorption in healthy term infants (n=40) [98]
Weight gain similar to breast-fed infants (n=96) [87]
Lactoperoxidase (LCP)
Improvement in the number and severity of xerostomia symptoms in elderly patients using Biotène® products 
(toothpaste, mouthwash and gel) with lactoperoxidase enzyme system and LF (n=20)
[70]
Improvement of symptoms in elderly patients with dry mouth using Biotène® mouthwash and Oral Balance® gel 
containing lactoperoxidase enzyme system, LF and lysozyme (n=20)
[31]
Significant reduction in the symptoms scores in patients with burning mouth syndrome using Biotène® oral rinse 
(LCP and lysozyme), oral rinse with capsaicin or tablets with α-lipoic acid (n=56)
[66]
No effects on accumulation and acidogenicity of dental plaques, salivary flow rate, peroxidase activity, thiocyanate 
levels and bacterial counts of lactoperoxidase enzyme system-containing Biotène® toothpaste applied in healthy 
volunteers with normal salivary flow rate (n=20)
[51]804
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Lactoperoxidase (LCP)
Lactoperoxidase enzyme system-containing Biotène toothpaste combined with Biotène® mouthrinse (comprising 
also LF and lysozyme) relieved the symptoms of oral dryness in patients with xerostomia in Sjögren’s syndrome, 
with no major effect in salivary microflora (n=20)
[50]
Alleviation of dry mouth symptoms by Oral Balance® gel (lactoperoxidase enzyme system, LF and lysozyme) for 4 
weeks in secondary Sjögren’s syndrome patients (n=21)
[4]
Combined use of Biotène® toothpaste with Oral Balance® gel (both with lactoperoxidase enzyme system) for 4 
weeks with good results in subjective relief of xerostomic symptoms; enhanced keratinization and decreased 
number of inflammatory cells in the buccal and mucosal smears
[88]
Biotène® toothpaste (lactoperoxidase enzyme system) applied in children with early childhood caries significantly 
reduced numbers of mutant streptococci and lactobacilli (n=30)
[46]
Tablets containing LF and LCP reduced oral malodor and number of salivary bacteria in subjects with volatile sulfur 
compounds in mouth air above the olfactory threshold (n=15)
[93]
Beneficial results in mouth scores in post-radiotherapy xerostomia in patients using Bioxtra® (“whey extract”) 
and Oral Balance® (lactoperoxidase enzyme system, LF and lysozyme) mouth dry systems in the treatment of 
postradiotherapy xerostomia (n=20)
[92]
Improved oral health, reduction of oral cariogenic bacteria in cancer patients after radiotherapy using lactoperoxi-
dase enzyme system-containing Oral Balance® gel (in bolus or slow-release form) for 4 weeks (n=22)
[72]
Improved salivary flow and increased oral comfort, reduction of aerobic isolates, periodontal-associated bacteria 
and Candida species by Oral Balance® gel and Biotène® toothpaste in irradiated patients with oral cancer for 4 
weeks following radiotherapy (n=36)
[76]
Reduced rate of supragingival plaque formation and gingival inflammation by Biotène® toothpaste (lactoperoxi-
dase enzyme system) in radiation induced xerostomia during 52-day period (n=20)
[108]
Improved gingival health, reduction of gingivitis by Biotène® toothpaste (lactoperoxidase enzyme system) in 
cancer patients after radiotherapy (n=19)
[102]
Subjective relief of radiation-induced xerostomic symptoms (e.g. oral discomfort, intraoral dryness, inability to eat 
normally) by combined use of Biotène® products (mouthwash, toothpaste, chewing gum) and Oral Balance® gel 
(n=28)
[110]
Increase in hydrogen peroxide concentration in exhaled breath condensate after inhibition of LCP by dapsone in 
nonsmoking asthmatic patients; suggested a potential role for LCP in scavenging of H2O2 in asthmatic airway 
[3]
Casein derivatives
Mouthrinse used for 12 months in radiotherapy patients and Sjögren’s syndrome patients with xerostomia; no 
significant differences in coronal caries between the test group and the control group (n=124)
[36]
In adult patients with severe xerostomia a good moistening and lubrication effect with Dentacal® mouth spray 
(n=38)
[35]
Adults volunteers drank 200 ml of control milk or test milk with CPP-ACP for 3 weeks; all milk samples were effec-
tive in remineralization of enamel surface, but test milk produced greater remineralization (n=10)
[109]
GC Tooth Mousse® applied on teeth of patients with dentin hypersensitivity caused by various factors; insufficient 
effectiveness and short-term therapeutic effect in soothing pain (n=13; 101 teeth)
[52]
β(1-25)-Fe labeled with iron 59, added to cow milk, was studied in young women (n=10) compared with control 
substance ferrous sulfate; although the absorption of β(1-25)-Fe was not significantly higher than that of control, 
it displayed significantly higher tissue uptake.
[2]
Single dose of casein hydrolysate (designed C12 peptide) either alone or combined with alginic acid in hyperten-
sive subjects led to significant decrease of systolic and diastolic blood pressure (n=10)
[103]
Antihypertensive effect in volunteers with high-normal pressure or mild hypertension taking casein hydrolysate  
containing ACE inhibitory tripeptides (VPP and IPP) in tablets for 6 weeks (n=131)
[74]
Improvement of vascular endothelial functions and no change in systemic blood pressure in casein hydrolysate 
(containing ACE inhibitory tripeptides) treated mild-hypertensive subjects for one week (n=25)
[38]
Casein hydrolysate tablets (with ACE inhibitory tripeptides) administered for 4 weeks caused mild improvement in 
hypertension without adverse effects (n=48)
[43]
Casein hydrolysate (with ACE inhibitory tripeptides) given for 8 weeks to aged subjects with untreated stage-I 
hypertension led to reduction of systolic blood pressure (n=70)
[77]
Nasogastric feeding with casein hydrolysate of elderly patients with ischemic stroke decreased IL-6 and increased 
glutathione serum levels (n=31)
[21]
7-day treatment with casein hydrolysate (insuVidaTM) alone or with additional leucine significantly lowered 
plasma glucose as compared to placebo or intact casein (n=36)
[30]805
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Lysozyme
A beneficial effect of breast milk or infant formula enriched in lysozyme in feeding premature infants suffering 
from concomitant diseases; after 14-21 days of this feeding the following were observed: increase of body weight, 
more rapid sanation of inflammatory foci, normalization of the stool and stabilization of lysozyme levels in serum 
and stool (n=64)
[11]
Preventive effect of lysozyme chloride given for 4-24 weeks before orthopedic surgery on post-transfusion hepatitis 
(n=260)
[89]
A synergistic effect of lysozyme with antibiotics as compared with antibiotics alone in treatment of acute pneumo-
nia (n=92) and pyelonephritis (n=83) children
[16]
Antiviral and antimicrobial effects in healthy volunteers infected with non-pathogenic strains of measles virus and 
attenuated Salmonella Typhi (n=14)
[32]
Effective in local treatment of crural ulcers refractory to previous treatment (n=20) [29]
Increase of immunological reactivity in patients with head and neck cancer treated for 6 months (n=16) [42]
Proline-rich polypeptide 
(PRP)
100 μg Colostrinin® tablets, every second day for 3 weeks, 2-week hiatus, 10 cycles, improved outcome in 
Alzheimer’s patients with mild to moderate dementia (n=46)
[58]
16-month trial (treatment as above), confirmation of the previous results (n=33) [57]
15-week treatment in a multi-center trial, beneficial effects on cognitive symptoms and daily function Alzheimer’s 
patients (n=105)
[9]
Ig concentrate from hyperim-
mune bovine milk
Protective effect in healthy volunteers against S. flexneri [99]
Protection against diarrhea in volunteers infected with enterotoxicogenic E. coli (n=25) [27]
No prophylactic effect against E. coli in healthy volunteers (n=20) [100]
Prophylaxis against rotavirus gastroenteritis in infants (n=10) [24]
Some, but not statistically significant improvement in treatment of acute rotaviral gastroenteritis in children 
(n=135)
[113]
Protective effect (less diarrhea and reduction in oocyst excretion) in healthy volunteers infected with C. parvum  
(n=16)
[79]
Amelioration of osteoarthritis symptoms (joint pain and stiffness and immobility) in adult patients (n=42) [116]
TGF-β (Modulen IBD®)
Remission in 80% of children with newly diagnosed CD and 58% with long-standing disease and improving 
nutritional status (n=27)
[20]
Clinical and histological remission (improvement of degree of inflammation of the intestinal mucosa) in pediatric 
CD patients (n=14)
[78 ]
Improvement in disease severity score (clinical response), body mass index and erythrocyte sedimentation rate in 
CD children as compared with standard polymeric formula and standard nutrition (n=64)
[34]
Clinical remission and mucosal healing (histological remission) and improvement in anthropometric measures in 
CD children (n=106)
[85]
Milk fat globule membrane 
proteins (MFGM)
Protective effect (lower incidence of diarrhea, severe diarrhea, prevalence and duration of diarrhea and numbers of 
children with persistent diarrhea) in Peruvian infants given complementary food with MFGM fraction for 6 months, 
as compared to control group given skim milk proteins (n=550)
[115]
Abbreviations used in Table: angiotensin-I-converting enzyme (ACE), casein phosphopeptide-amorphous calcium phosphate (CPP-ACP); Crohn’s disease (CD); glycomacropeptide (GMP); 
human α-lactalbumin made lethal to tumor cells (HAMLET); immunoglobulins (Ig); α-lactalbumin (LA); lactoperoxidase (LCP); lactoferrin (LF); large neutral amino acids (LNAA); milk fat 
globule membrane proteins (MFGM).
Table 2. Bioactive peptides derived from bovine milk proteins (examples)
Peptides (name) Origin Fragments Structure Function References
β-Lactotensin LG (146-149) HIRL
Ileum contraction, hypertensive activity, 
memory consolidation, blood cholesterol 
reduction
[53,91]
Lactokinin LG (142-148) ALPMHIR ACE inhibitor [19,26,91]
β-Lactosin LG (142-145) ALPM ACE inhibitor [19]
β-Lactorphin LG (102-105) YLLF
ACE inhibitor, opioid agonist, stimulatory 
effect on ileum
[44,53,91]
– LG (71-75) IIAEK Hypocholesterolemic effect [19,105]
cd. Table 1. Published clinical studies with milk proteins and peptides
Protein/peptide Clinical effects, number of participants References806
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α-Lactorphin LA (50-53) YGLF ACE inhibitor, opioid agonist [26,53,91]
LDT1 LA (1-5) EQLTK Antibacterial activity [19,105]
LDT2 LA (17–31)S-S(109–114) GYGGVSLPEWVCTTFALCSEK Antibacterial activity [19,105]
LDC LA (61–68)S-S(75–80) CKDDQNPHISCDKF Antibacterial activity [19,105]
Casokinins
αs1-casein
(23-24) FF
ACE inhibitor [19,26,105]
(23-27) FFVAP
(23-34) FFVAPFPEVFGK
(146-147) YP
αs2-casein
(174-179) FALPQY
ACE inhibitor
[19,26]
(198-202) TKVIP
β-casein
(74-76) IPP
ACE inhibitor [19,26,105]
(84-86) VPP
(88-90)  LQP
 (193-202) YQEPVLGPVR
κ-casein (108-110) IPP ACE inhibitor [19]
Casoxins κ-casein
(38-39) YG
Opioid antagonist
[91,105]
(35-42) YPSYGLNY
GMP κ-casein (106-169) Various fragments
Antithrombotic effect, immunomodulatory 
effect, antibacterial activity
[53,91]
β-Casomorphins β-casein
(60-66) YPFPGPI
Opioid agonist
[19,44,105]
(60-64) YPFPG
α-Casein exorphins 
(α-casomorphins)
α s1-casein
(90-96) RYLGYLE
Opioid agonist
[19,91]
(90-95) RYLGYL
Isracidin α s1-casein (1-23) RPKHPIKHQGLPQEVLNENLLRF
Antibacterial activity, immunomodulatory 
effect
[19,105]
Casocidin-I α s2-casein (165-203)
KKISQRYQKFALPQYLKTVYQHQKAM 
KPWIQPKTKVIPY
Antibacterial activity
[19,105]
Casopiastrin κ-casein (106-110) MAIPP Antithrombotic activity [91,105]
– α s1-casein (79-81) KHI Immunomodulatory effect [19,105]
– αs2-casein (1-32)
KNTMEHVSSSEESIISQETYKQEK 
NMAINPSK
Immunomodulatory effect
[19,105]
– β-casein
(63-68) PGPIPN
Immunomodulatory effect
[19,105]
(191-193) LLY
– αs1-casein (107-108) PQ Antioxidant activity [19]
Casein 
phosphopeptides
αs1-casein
(43-58) DIGSESTEDQAMEDIK
Mineral carries, anti- caries activity [19,91,105] (66-74) SSSEEIVPN
(106-119) VPQLEIVPNSAEER
αs2-casein
(2-21) NTMEHVSSSEESIISQETYK
Mineral carries, anti-caries activity [19,91,105] (55-75) GSSSEESAEVATEEVKITVDD
(126-136) EQLSTSEENSK
β-casein
(1-25) RELEELNVPGEIVESLSSSEESITR
Mineral carries, anti-caries activity [13,19,91,105]
(1-28) RELEELNVPGEIVESLSSSEESITRINK
Abbreviations used in table: glycomacropeptide (GMP); α-lactalbumin (LA); β-lactoglobulin (LG); CLN – Colostrinin; A – Ala (alanine); E – Glu (glutamic acid); F – Phe (phenylalanine); 
G – Gly (glycine); H – His (histidine); I – Ile (isoleucine); L – Leu (leucine); M – Met (methionine); N – Asn (asparagine); P – Pro (proline); Q – Gln (glutamine); R – Arg (arginine); 
S – Ser (serine); V – Val (valine); W – Trp (tryptophan); Y – Tyr (tyrosine). Amino acid sequences of functional protein chains (without signal peptides) of bovine proteins are presented. 
Protein chain and precursor sequences (that include signal peptides) are the following for: αS1-casein – 214 residues includes the signal sequence 1-15, αS2-casein – 222 residues with 
signal sequence 1-15, β-casein – 224 residues with signal sequence 1-15; κ-casein – 190 residues with signal sequence 1-21, LA – 142 residues with signal sequence 1-19 and LG – 178 
residues with signal sequence 1-16 [105].
cd. Table 2. Bioactive peptides derived from bovine milk proteins (examples)
Peptides (name) Origin Fragments Structure Function References807
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cose, insulin and blood pressure decreased and HDL cho-
lesterol increased) [48]. However, whey protein- and whey 
protein-LA-enriched breakfast yoghurt drink increased 
energy expenditure and protein balance and decreased 
fat balance compared to control breakfast (whole milk). 
In addition, the LA-enriched yoghurt suppressed hunger 
more than the whey-enriched yoghurt [40]. In another 
double-blind 12-week study obese subjects drank the Pro-
libraTM beverage (Glanbia Nutritionals Inc.) which conta-
ins a combination of intact whey proteins and peptides 
and minerals purified from bovine milk. The supplement 
is high in leucine, bioactive peptides and calcium. The 
control group received an iso-caloric beverage containing 
maltodextrin, with a lower calcium and protein content. 
The supplementation with ProlibraTM increased the loss of 
body fat and the retention of lean muscle mass compared 
to supplementation with a control drink [28].
The formulas enriched in α-lactalbumin and GMP were 
also tested in various pathological conditions. A diet rich 
in LA hydrolysate was applied in malnourished children 
with diarrhea of various degree [25]. The results showed 
better weight gain and requirement of a smaller number 
of rehydrations during the first three weeks of hospita-
lization as compared to the control group. However, in 
a clinical trial involving children with diarrhea, where 
three different rehydration solutions were tested, no ad-
vantage of LA-containing formula over two other solu-
tions in terms of stool output and duration of diarrhea 
was found [86]. Because of lack of phenylalanine, GMP is 
an attractive candidate for a diet of individuals suffering 
from phenylketonuria [55,106]. The authors compared a 
GMP-containing diet with phenylalanine-free amino acid 
formula in subjects with phenylketonuria and found that 
the experimental diet was well tolerated and improved 
protein retention and phenylalanine utilization as com-
pared to the control diet. In addition, the GMP-containing 
diet lowered the plasma ghrelin (appetite-stimulating 
hormone) levels in such patients, which was associated 
with greater feelings of satiety [65]. In phenylketonuria 
patients complaints of persistent hunger are common. A 
skim milk powder enriched with GMP and milk fat extract 
was used in a randomized, double-blind 3-month trial for 
prevention of gout flares [18]. Control groups received 
lactose powder or skim milk powder. Although improve-
ment in the studied parameters (pain, excretion of uric 
acid) was seen in all groups, only the GMP-enriched for-
mula gave statistically significant results as compared 
with baseline conditions of patients. 
A series of trials were also performed aimed at evaluation 
of effects of α-lactalbumin on mood, stress and memory. 
Brain serotonin, which is synthesized from tryptophan 
(W; Trp), influences food intake and mood [114] and Trp 
content is high in α-lactalbumin [37]. Trp uptake in the 
brain is dependent on the plasma ratio of Trp to the sum 
of other large neutral amino acids (LNAA). The effect of 
an LA supplement combined with regular diet on several 
parameters such as plasma Trp:LNAA ratio, serum pro-
lactin as a marker of serotonin synthesis, food intake, 
appetite, macronutrient preference and mood was stu-
died in healthy males as compared to a regular diet [8]. 
Although the plasma Trp:LNAA ratio was significantly in-
creased after the experimental diet, the authors could not 
demonstrate effects of that diet on appetite, food intake, 
macronutrient preference and mood. Other investigators 
[73] also were not able to show any effect of a one-day diet 
enriched in LA on stress-induced mood deterioration in 
depressed patients and healthy subjects, although the LA 
diet led to the expected rises in Trp:LNAA ratio. However, 
the same group of researchers [12] found in the catego-
ry of recovered depressed patients that the LA-enriched 
diet improved abstract visual memory and impaired sim-
ple motor performance with no effect on mood. Other 
researchers focused predominantly on the effects of an 
LA-enriched diet on stress and sleepiness [67,68,69]. In 
subjects exposed to experimental stress after the intake 
of an LA-enriched diet the plasma Trp:LNAA ratio was 
higher by 48% than in subjects taking a control, sodium 
caseinate-enriched diet [69]. The stress-vulnerable sub-
jects fed the experimental diet also had higher prolactin 
concentrations, decreased cortisol levels and reduced 
depressive feelings under stress. In the same category of 
patients the authors [68] demonstrated an advantageous 
effect of an LA diet on cognitive performance. In another 
study by the same group [67] healthy subjects with sleep 
complaints were given in the laboratory evening meals 
containing α-lactalbumin or tryptophan-low placebo. The 
experimental meal significantly increased the Trp:LNAA 
ratio, reduced sleepiness and improved brain-sustained 
alertness the next morning. A trial on women with pre-
menstrual complaints showed that LA improved long-
-term memory for abstract figures but not for words [90].
α-Lactalbumin may be converted from its native regular 
state to a partially unfolded variant [96]. Such a variant 
of LA with a specific fatty acid (oleic acid C18:1) cofactor 
induces apoptosis of tumor and immature cells and is de-
fined as HAMLET (human α-lactalbumin made lethal to 
tumor cells). The authors suggest that a similar complex 
may be formed in the stomach of a nursing child. In a 
clinical trial on patients with cutaneous papillomas HAM-
LET proved to be very effective in reducing both volume 
and occurrence of the lesions [33]. It also appeared that 
intravesical HAMLET application (25 mg/ml for 5 con-
secutive days) to bladder cancer patients before surgery 
resulted in increased shedding of dead tumor cells into 
the urine [75]. Upon surgery, the morphological changes 
and reduction in tumor size were confirmed. The adjacent 
healthy tissue showed no evidence of apoptosis or toxic 
response. The authors propose that local administration 
of HAMLET might be of value in treatment of bladder 
cancers. Bovine α-lactalbumin and oleic acid (BAMLET) 
also demonstrated anticancer properties, but, as yet, it 
was applied only in in vitro models [19].
lactoperoxIdase
Lactoperoxidase (LCP) constitutes approximately 0.5% of 
whey proteins in bovine milk and only <0.1% in human 808
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milk (Fig. 1). LCP has potent antibacterial and antifungal 
activities in the presence of hydrogen peroxide (H2O2) 
[111]. The enzyme catalyses the oxidation of thiocya-
nate (SCN–) and produces intermediate products (–OSCN/
HOSCN) with antimicrobial activities. Such properties 
prompted investigators to apply lactoperoxidase-contain-
ing preparations in clinical trials in healthy subjects and 
patients. Results of these trials enabled pharmaceutical 
companies to launch cosmetics and oral hygiene prod-
ucts with LCP. To make LCP antimicrobial, its substrate 
(SCN–) is added as potassium thiocyanate (KSCN), but H2O2 
is generated in situ in the mouth by a glucose-glucose 
oxidase system added to these oral hygiene products. 
All components constitute together the “lactoperoxidase 
enzyme system” [101]. Other antimicrobial host proteins 
– lysozyme and lactoferrin (LF) – act in an additive and 
even synergistic way; therefore they are often combined 
with the lactoperoxidase enzyme system in oral health 
care products. A number of oral hygiene products/saliva 
substitutes have been developed during the last decades. 
They include not only toothpaste, but also non-alcoholic 
mouth-rinse, chewing gum, moisturizing gels and den-
ture adhesives for patients with dry mouth problems. For 
commercial purposes bovine enzymes (LCP, LF and lyso-
zyme) purified from colostrum or milk have been used be-
cause they are structurally and catalytically very close to 
human enzymes, and large-scale purification from human 
material is difficult and too expensive [reviewed in 101].
For example, the Biotène Oral Balance® gel (Lacléde Inc. 
Healthcare Products) is a saliva substitute product which 
contains the lactoperoxidase enzyme system and LF and 
proved to be effective in reducing symptoms of dry mouth 
(xerostomia) in the elderly [70]. Likewise, the clinical effi-
cacy of the Biotène Oral Balance® gel and Biotène® mouth-
wash containing the lactoperoxidase enzyme system, LF 
and lysozyme in elderly subjects with xerostomia was also 
demonstrated [31]. Both hyposalivation and xerostomia 
increase with age and are often associated with frequent 
use of drugs. These symptoms may have a negative impact 
on the quality of life. They may lead to risk of oral infec-
tions, increased rate of dental caries, mucosal atrophy, 
burning and pain. In another clinical study on patients 
with burning mouth syndrome several preparations con-
taining capsaicin (red pepper emulsion in water), α-lipoic 
acid in tablets (Tiobec®; Laborest Italia S.P.A.) or lysozyme-
lactoperoxidase in oral rinse (Biotène®) as test drugs and 
boric acid as control were tested [66]. All of the treat-
ments were more effective than boric acid. On the other 
hand, a double-blind crossover study with 20 healthy 
volunteers with normal salivary flow rate did not show 
any advantageous effect of 2-week use of lactoperoxidase 
enzyme system-containing toothpaste (Biotène®) on sali-
vary flow rate, peroxidase activity, thiocyanate (–OSCN/
HOSCN, SCN–) and total streptococci, mutans strepto-
cocci, lactobacilli and anaerobic flora in saliva and den-
tal plaques [51]. In another study the same authors used 
hygiene products (Biotène® toothpaste and mouthrinse) 
consisting of lactoperoxidase enzyme system, lysozyme 
and LF in 20 patients with xerostomia in Sjögren’s syn-
drome. They registered a relief from the symptoms of oral 
dryness, although no increase in salivary flow rate or its 
hypothiocyanate levels were found. No major changes 
occurred in salivary microflora either [50]. Biotène Oral 
Balance® gel containing lactoperoxidase enzyme system, 
LF and lysozyme also proved effective in 21 secondary 
Sjögren’s syndrome patients with dry mouth complaints 
and hyposalivation, based on a 7-item questionnaire (dry 
mouth sensation and its effect on chewing, swallowing, 
taste, speech, burning sensation and denture reten-
tion) [4]. The lactoperoxidase enzyme system-contain-
ing products Biotène Oral Balance® gel in combination 
with Biotène® toothpaste were effective in symptomatic 
therapy in patients suffering from dry mouth syndrome 
with diseases of the oral mucosa [88]. Therefore, stud-
ies with patients with xerostomia/hyposalivation are of 
greater interest than those with healthy subjects with 
normal salivation. 
Also promising results were obtained with the Biotène® 
toothpaste containing lactoperoxidase enzyme system 
(which has inhibitory action against cariogenic oral mi-
croflora) in children with early childhood caries [46]. It 
appeared that, in comparison to a control group (Colgate 
Active® toothpaste), the levels of thiocyanate ions were 
increased and the numbers of mutans streptococci and 
lactobacilli were significantly reduced during the experi-
mental period. In a clinical trial with 15 subjects, tablets 
containing bovine LF and LCP (Morinaga Milk Industry) 
were effective in reducing oral malodor (volatile sulfur 
compounds in mouth air) and the number of salivary 
bacteria [93]. Radiotherapy of head and neck cancer is 
associated with xerostomia [17]. In a study on patients 
with post-radiotherapy xerostomia the efficacy of two 
lactoperoxidase-containing preparations, Bioxtra® (Light-
house Health Products Inc.) and Biotène Oral Balance® 
dry mouth systems, were investigated, with comparable, 
beneficial results on mouth scores [92]. Bioxtra®, which 
contains additional peptides from “whey extract” or co-
lostrum (e.g. immunoglobulins, growth factors), was a 
little more effective in relieving the symptoms of xero-
stomia than Biotène Oral Balance®. In another clinical trial 
a comparison was made between Biotène Oral Balance® 
gel delivered to post radiotherapy-related xerostomia 
patients in two ways: by slow release via a novel intra-
oral device or as an oral bolus [72]. The results showed 
that this gel, both in bolus and slow-release form, was 
equally effective in reduction of xerostomia symptoms 
and oral cariogenic microorganisms. Similar results were 
obtained in irradiated oral carcinoma patients with daily 
use of Biotène Oral Balance® gel and Biotène® toothpaste 
in combination, for 4 weeks after radiotherapy [76]. Con-
trol subjects received carboxymethylcellulose gel and 
Oral B® fluoride toothpaste. The treatment improved sali-
vary flow and increased oral comfort in comparison to 
the control group. In addition, some aerobic isolates of 
microorganisms were eliminated, and periodontal-asso-
ciated bacteria and candidal species were significantly 
lowered in the experimental group. Other studies with 
patients having radiation-induced hyposalivation/xe-809
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rostomia have shown the efficacy of Biotène® toothpaste 
containing lactoperoxidase enzyme system in control 
of gingival disease. The test toothpaste examined in 20 
patients during a 52-day period reduced the rate of su-
pragingival plaque formation and gingival inflammation 
compared with a control toothpaste [108]. A double-blind 
crossover study with 19 patients with irradiated head and 
neck cancer who had used the Biotène® toothpaste showed 
reduction of gingivitis [102]. Another study combined lac-
toperoxidase enzyme system-containing Biotène® prod-
ucts (toothpaste, mouthwash, chewing gum) and Biotène 
Oral Balance® with good results in subjective relief of radi-
ation-induced xerostomic symptoms (e.g. oral discomfort, 
intraoral dryness, inability to eat normally). The lack of 
an appropriate control makes it, however, impossible to 
rule out the placebo effect [110]. In 2012 a randomized 
trial was completed applying Biotène Oral Balance® gel 
in 41 critically ill mechanically ventilated newborns [1]. 
Prolonged mechanical ventilation is a known risk factor 
strongly associated with ventilator associated pneumonia 
(VAP), which is caused by a profuse access of microflora 
in the oral cavity. Therefore, application of the antimi-
crobial gel may diminish the incidence of pulmonary in-
flammation in these children. The results of this trial are 
not available as yet (April 2013).
Hydrogen peroxide generated by neutrophils and eosi-
nophils in asthma is known to damage the airway epi-
thelium and to contribute to airway inflammation [39]. 
In an observational study by Al Obaidi et al. an attempt 
was undertaken to evaluate the contribution of lactope-
roxidase in scavenging airway hydrogen peroxide and to 
propose a therapeutic approach for asthma [3]. Nonsmo-
king asthmatic patients enrolled in the study were admi-
nistered dapsone (a lactoperoxidase inhibitor) for 8 weeks 
and hydrogen peroxide concentration in exhaled breath 
condensate was determined. Determination of hydrogen 
peroxide content revealed its significant increase when 
compared to the baseline. The results suggest a poten-
tial beneficial role for lactoperoxidase in scavenging of 
hydrogen peroxide in asthmatic airways.
caseIns
Caseins constitute a large part (80%) of total proteins in 
bovine milk and a minor part (20-50%) of total proteins 
in human milk. The major constituents of the family of 
bovine caseins are β- and αS1-caseins, and of human ca-
seins – β- and κ-caseins (Fig. 1). Caseins not only provide 
adequate amounts of essential amino acids, but peptides 
derived from caseins have been shown to express vari-
ous biological effects (Table 2). Bioactive peptides are 
produced by in vitro and in vivo enzymatic proteolysis of 
bovine and human caseins [19,91]. 
Casein derivatives were tested in treating dry mouth, den-
tin hypersensitivity and in caries prevention (reviewed 
in [6]). In a randomized clinical trial with subjects with 
salivary gland dysfunction (radiotherapy and Sjögren’s 
syndrome patients) two mouthrinse solutions contain-
ing either casein derivatives with calcium phosphate or 
a 0.05% sodium fluoride (as control), used for 12 months, 
were compared [36]. No statistically significant differ-
ences between the two groups regarding coronal caries 
were found. A good moistening and lubrication effect of a 
phosphoprotein-calcium phosphate complex (Dentacal®; 
NSI Pty Ltd.), in the form of mouth spray, was obtained in 
a category of patients with severe xerostomia [35]. In a 
double-blind, crossover study 10 adult volunteers drank 
200 ml of control milk or test milk with 2 or 5 grams of 
casein phosphopeptide-amorphous calcium phosphate 
(CPP-ACP), once a day for 3 weeks. The results demon-
strated that all 3 milk samples remineralized enamel sub-
surface lesions, but milk with CPP-ACP produced greater 
remineralization than the control milk [109]. The aim of 
the next study was to evaluate the efficiency of GC Tooth 
Mousse® (GC Corporation), based on the RecaldentTM tech-
nology, with CPP-ACP in the treatment of patients with 
dentin hypersensitivity caused by various factors. The 
product was applied on surfaces of teeth for 3 minutes 
and pain intensity was tested. The study concluded that 
the efficacy and short-term therapeutic effect of CPP-ACP 
were insufficient [52].
The casein phosphopeptides (CPP) – strongly phosphory-
lated peptides obtained by enzymatic digestion of caseins 
– have a strong capacity to fix nutritionally interesting 
divalent cations such as calcium, iron or zinc, thus mak-
ing them stable and soluble in different physico-chemical 
conditions, in particular of pH. Due to this property, CPP 
may be involved in intestinal absorption of minerals, in 
particular of calcium. The results of research are, how-
ever, contradictory (reviewed in [13]). CPP improve the 
absorption of calcium in the rat by limiting the precipita-
tion of this mineral in the intestine and also the absorp-
tion of calcium and zinc in the human adult, but do not 
show a positive effect in other studies in the rat or pig. 
The phosphopeptide β(1-25) derived from bovine β-casein 
that contains 4 phosphoserine residues in its sequence 
and can fix 4 to 5 iron atoms with a high affinity was 
studied in rats and humans [13]. The studies in rats dem-
onstrated the efficiency of β(1-25) on the absorption and 
bioavailability of iron, and the efficiency was confirmed 
in a first clinical study comparing Fe/β(1-25) and iron 
sulfate. The quantity of iron stored in the organs seven 
days after the ingestion of the preparations was higher 
in the group having received the Fe/β(1-25) complex [2]. 
These beneficial results may partly explain the high iron 
bioavailability of breast milk, which is rich in β-casein.
Casein hydrolysates were, on the other hand, applied in 
clinical trials of hypertensive subjects (reviewed in [26]). 
It appeared that proteolytic digest of casein by bacterial 
enzymes lowered blood pressure in spontaneously hyper-
tensive rats due to release of angiotensin-I-converting 
enzyme (ACE, EC 3.4.15.1) peptide inhibitors [112]. In a 
first small placebo-controlled crossover trial two single 
doses of bovine casein hydrolysate (designed C12 pep-
tide), administered alone or in combination with alginic 
acid, significantly reduced systolic and diastolic blood 810
Postepy Hig Med Dosw (online), 2013; tom 67: 800-816
pressure in 10 hypertensive subjects [103]. In a larger sin-
gle-blind, placebo-controlled study with 131 volunteers 
with high-normal blood pressure and mild hypertension, 
a casein hydrolysate, containing the major ACE inhibi-
tory tripeptides VPP and IPP, was used in four different 
doses (in tablets) for 6 weeks. An antihypertensive effect 
was demonstrated, particularly in mildly hypertensive 
subjects [74]. In another study in humans with mild hy-
pertension the casein hydrolysate containing the same 
antihypertensive tripeptides improved vascular endothe-
lial functions independently of blood pressure-lowering 
effects [38]. It also appeared that a large excess (5 times 
more than the effective amount) of casein hydrolysate-
containing tripeptides, given in tablets, reduced systolic 
blood pressure in subjects with mild hypertension, but 
not in normotensive subjects. In addition, neither an ex-
cessive reduction in blood pressure nor other adverse 
events were observed [43]. Lastly, casein hydrolysate con-
taining the active tripeptides improved blood flow pa-
rameters in a double-blind, placebo-controlled trial in 
aged subjects with untreated stage-I-hypertension [77]. 
Casein or whey hydrolysate nutrition formulas, admin-
istered by nasogastric feeding, were used in elderly pa-
tients with acute ischemic stroke [21]. The mortality in 
both groups of patients was similar (33%). The parameters 
measured were: serum interleukin (IL)-6, C-reactive pro-
tein (CRP) and glutathione levels. Serum IL-6 concentra-
tion decreased and glutathione levels were significantly 
higher in whey-protein fed patients in comparison to the 
casein group. The authors conclude that whey protein 
enteral formula in ischemic stroke patients may decrease 
inflammation and increase antioxidant defense compared 
to casein-containing formula.
On the other hand, hydrolyzed casein was found effective 
in decreasing postprandial glucose concentrations in type 
2 diabetes mellitus patients who continued their oral an-
ti-diabetic medication [30]. In a double-blind trial single 
meal replacements with proprietary casein hydrolysate 
(insuVidaTM; DSM Nutritional Products) alone or with ad-
dition of leucine, unhydrolyzed casein or placebo were 
used. Postprandial serum glucose, insulin and glucagon 
concentrations were measured after 4 h. The addition of 
leucine to insuVidaTM caused the biggest increase in in-
sulin (by 51.8%). All three treatments increased glucagon 
concentration compared to placebo. In addition, a single 
dose of insuVidaTM with or without leucine significantly 
lowered plasma glucose content compared to placebo and 
intact casein. The results suggest a benefit of the studied 
nutrients in management of type 2 diabetes.
Some peptides from caseins show pharmacological simi-
larities to opium (morphine) and are called “opioid pep-
tides”. The major opioid peptides, called β-casomorphins 
and α- casomorphins, are fragments of β- and α-casein, 
respectively. Opioid peptides are opioid receptor agonists 
and they induce an analgesic and sedative effect due to 
their action on the nervous system. They also affect the 
gastrointestinal motility. However, all κ-casein fragments, 
known as casoxin, behave as opioid antagonists. Opioid 
agonists and antagonists may be formed in the gut as a 
result of in vivo hydrolysis of milk caseins [19,91]. Several 
immunomodulating peptides can be released from α- and 
β-caseins, whereas the κ-casein fragment (casopiastrin) 
shows antithrombotic activity [91]. β-casein and its pep-
tides, as well as αs-casein, possess antioxidant and anti-
microbial activity [19] (Table 2). As yet, however, none of 
the above-mentioned peptides has been clinically tested. 
lysozyme
Lysozyme is present in human milk at relatively high con-
centrations (about 6% of the total whey proteins), while in 
bovine milk it is present at minor concentrations (<0.1% 
of the total whey proteins) (Fig. 1). This enzyme is known 
to degrade the outer cell walls of Gram-positive bacteria, 
but together with lactoferrin is able to kill also Gram-ne-
gative bacteria. Lysozyme is widely used as a food prese-
rvative, in infant feeding formulas and in pharmaceutical 
products for treatment of periodontitis, dry mouth syn-
drome and prevention of tooth decay (reviewed in [82]) 
but its application in clinical trials is limited. 
Breast milk or dry adapted milk formula enriched in ly-
sozyme (50 mg/L) was used in feeding premature infants 
suffering from concomitant diseases. The control group 
was fed breast milk or an artificial product without lyso-
zyme. A beneficial effect was shown, as compared to that 
of control, taking into account increase in body weight, 
sanation of the infectious inflammatory foci, normaliza-
tion of the stool, and stabilization of lysozyme levels in 
the coprofiltrates and in the blood serum [11]. In a large 
randomized controlled trial a preventive effect of lysozy-
me on post-transfusion hepatitis in orthopedic diseases 
was studied. The patients who received blood transfusion 
during a period of 5 years (1970-1975) were given lysozy-
me chloride (60 to 170 mg/day) from 4 to 24 weeks. The 
incidence of post-transfusion hepatitis was 8.1% for the 
treated group in contrast to 20.4% for the control group 
[89]. Lysozyme was also used as an antimicrobial agent 
showing synergistic effects in combination with different 
classes of antibiotics such as benzylpenicillin, ampiox, 
morphocycline, erythromycin and others, and amino-
glycosides such as gentamycin, tobramycin, sisomicin 
and amikacin in vitro [16]. The authors confirmed these 
co-stimulatory, antibacterial effects in patients (children) 
with acute pneumonia and pyelonephritis of bacterial 
genesis. In case of pneumonia the combined action of 
lysozyme and conventional antibiotics resulted in more 
rapid elimination of fever, toxic and cardiorespiratory 
syndromes, cough and other signs of the disease. In the 
group of children suffering from pyelonephritis complete 
clinico-laboratory remission was observed in 81% of pa-
tients compared to 56.4% of cases treated with antibiotics 
alone. The antiviral and antimicrobial effects were also 
proved in healthy volunteers infected with non-patho-
genic vaccine strains of living measles virus and of at-
tenuated Salmonella Typhi [32]. A therapeutic action of 
local lysozyme treatment (solution in 0.9% NaCl, 1 mg/811
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mL) was also found in the case of crural ulcers [29]. That 
action was not due to effects of lysozyme on ulcer-asso-
ciated bacterial flora since the cultured bacteria were 
insensitive in vitro to lysozyme concentrations applied in 
vivo. The authors suggested that the beneficial effect of 
lysozyme on wound healing could be due to its cationic 
influence on the cell membranes of the epithelium and 
to pH change in the ulcerations. It was also demonstra-
ted that long-term treatment of head and neck cancer 
patients with lysozyme chloride during standard therapy 
led to a significant increase of the intradermal respon-
se to antigens phytohemagglutinin (PHA) and purified 
protein derivative (PPD) intradermal injections [42]. The 
patients had no local or systemic unfavorable effects due 
to lysozyme [11,29,42].
prolIne-rIch polypeptIde (prp)
Proline-rich polypeptide (PRP) is a uniform mixture of 
low-molecular-weight proline-rich polypeptide with im-
munoregulatory properties (reviewed by [117]). PRP was 
originally isolated from ovine colostrum in 1974 [45] and 
then named colostrinine (CLN) [41]. The immunoregula-
tory properties of PRP were, in part, also shared by its 
nonapeptide (VESYVPLFP) fragment [95]. PRP was subse-
quently shown to induce TNF-α, IFN-γ and IL-6 in human 
whole blood cultures and to exert psycho-stimulating ef-
fects in a pilot study in healthy volunteers [41,81]. It soon 
appeared evident that PRP is a very complex fraction, 
consisting of 32 peptides, and possessing homology to 
three protein precursors (annexin, β-casein and a hypo-
thetical β-casein homolog) [54]. PRP shows immunomod-
ulatory properties in mice, rats and chickens, inducing 
maturation and differentiation of thymocytes, induces 
neurite outgrowth of pheochromocytoma cells, extends 
the lifespan of fibroblast cells, and inhibits β-amyloid-
induced apoptosis. Interestingly, the PRP complex was 
also shown to decrease hypersensitivity and allergic re-
sponse to common allergens (house dust mites and rag-
weed pollen grains) in a mouse model [10]. The discovery 
that PRP promoted precognitive functions in experimen-
tal animal models, indicating prevention of pathological 
processes of the central nervous system, led to appli-
cation of CRP in clinical trials with Alzheimer′s disease 
(AD) patients.
In the first clinical trial PRP isolated from ovine colos-
trum (commercial name ColostrininTM; ReGen Thera-
peutics Ltd.) was applied as 100 µg tablets in AD patients 
for a one-year period [58]. Tablets supplemented in se-
lenium and placebo were used for control groups. The 
treatment was performed as cycles with a 2-week hia-
tus to avoid development of hyporeactivity. The results 
were assessed by psychiatrists blinded to the treatments 
assignment. It appeared that in 8 out of 15 patients the 
monitored parameters were improved whereas in the 
7 others the disease was stabilized. No improvements 
in health status were registered in two other (controls) 
groups. The next 2 trials were performed according to 
the protocol described above. A long-term (16 months) 
study confirmed the beneficial effect of ColostrininTM 
treatment with very mild adverse side-effects [57]. The 
results of these studies were verified in six psychiatric 
centers in Poland [9]. The full analysis of this double-
blind trial encompassed: Alzheimer′s Disease Assess-
ment Scale-cognitive portion (ADAS-cog), Clinical Global 
Impression of Change (CGIC), Instrumental Activities 
of Daily Lining (IADL), Mini-Mental State Examination 
(MMSE) and ADAS-non cognitive test (ADAS-non cog) 
and overall Patient Response. The results were in fa-
vor of the CLN experimental group as compared to pla-
cebo (ADAS-cog, p=0.02; IADL, p=0.02; overall Patients 
Response, p=0.03). Thus, these observations indicate a 
beneficial effect of ColostrininTM on cognitive symptoms 
and daily functions in AD patients. ColostrininTM, as a 
very promising preparation, has been used for several 
years to retard the development of AD.
In order to explain the mechanisms of action of CLN in 
the AD patients human neuronal SHSY-5Y cells were 
pretreated with CLN for 24 h [22]. The authors demon-
strated that CLN reduced β-amyloid-inducible apop-
tosis of these cells. In another study the gene expres-
sion profile of human buccal mucosal cell line TR146, 
treated in culture with 100 μg/ml of CLN, was investi-
gated [97]. The results showed that CLN elicited complex 
and multiphasic changes in the cells’ transcription pro-
cess. Of note, CLN altered gene expression implicated in 
β-amyloid precursor protein synthesis, Tau phosphory-
lation and increased levels of β-amyloid-degrading en-
zymes. In addition, CLN enhanced the defense against 
oxidative stress and decreased expression of genes for 
inflammatory cytokines, which suggests suppression of 
the inflammatory processes preceding the Alzheimer’s 
and other neurological diseases.
other mIlk-derIved products
Secretory IgA is the predominant immunoglobulin (Ig) 
in human milk. It is present in very high concentrations 
during early lactation and in lower but substantial con-
centrations throughout lactation. IgG is the predominant 
Ig in bovine milk (Fig. 1). The absorption of Ig from colo-
strum and milk provides passive immunity for newborns. 
High concentration of antibodies against a particular pa-
thogen may be achieved by immunizing cows with the pa-
thogen or its antigens. By combination of an appropriate 
strategy of vaccination and established production pro-
cedures in the dairy industry, large scale manufacture of 
various neutralizing IgGs is possible. On average, 500 g/
liter of IgG can be harvested from each immunized cow 
immediately after calving.
Concentrates of Ig derived from milk or colostrum of 
hyperimmunized cows were found to be protective in 
prevention of some infections, e.g. with Shigella flexneri 
or virulent strains of Escherichia coli. In a randomized, 
double-blind trial, volunteers were given a hyperim-
mune Ig concentrate with a high titer of anti-S. flexneri 
2a lipopolysaccharide (LPS) antibodies three times a day 812
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for seven days [99]. The volunteers were subsequently 
challenged with 103 colony forming units (CFU) of S. 
flexneri. Interestingly, none of the subjects from the ex-
perimental group became ill, in contrast to the placebo 
group (45% ill persons). Thus, high-titered, orally admin-
istered bovine Ig concentrate protects against shigello-
sis and may by useful in preventing this disease among 
travelers, military personnel and individuals during Shi-
gella outbreak. To find a preventive measure for diarrhea 
caused by enterotoxigenic E. coli (ETEC), a hyperimmune 
bovine milk antibody product was obtained containing 
antibodies against purified colonization factor antigens 
[27]. The product protected volunteers (14 out of 15) 
in comparison to a control, placebo group (3 out of 10) 
challenged orally with a virulent ETEC. Yet in another 
trial by these authors no effect of such a product on diar-
rhea in volunteers challenged with ETEC strain E24377A 
was found [100]. 
The hyperimmune milk products were also tested in 
prophylaxis and treatment of virus infections. A colos-
trum product, containing neutralizing antibody to dif-
ferent serotypes of human rotavirus, was used for two 
weeks in infants from a baby center, with advantageous 
results [24]. Rotavirus-associated diarrhea developed 
in 7 of the 10 infants in the control group and one of 
6 infants in the experimental group (receiving the co-
lostrum) had such symptoms. On the other hand, the 
efficacy of hyperimmune bovine colostrum from cows 
immunized with simian rotavirus SA11 in the treatment 
of rotaviral gastroenteritis was compared to ordinary 
colostrum or milk preparations in a large randomized, 
double-blind study involving 135 children aged 6-30 
months [113]. Even though differences were observed 
in weight gain, shorter duration of diarrhea and fewer 
stools, they were statistically insignificant. The authors 
suggest that these differences are clinically unimport-
ant in well-nourished immunocompetent children, but 
the tested hyperimmune colostrum had some effects 
and should be evaluated further.
A bovine hyperimmune anti-Cryptosporidium colostrum 
preparation was also effective in prophylaxis of vol-
unteers challenged with the parasite C. parvum [79]. A 
trend toward lower incidence of diarrhea was observed 
in the experimental group, as well as a strong reduction 
in oocyst excretion in comparison with the respective 
control group. A concentrated form of hyperimmune 
milk product (milk protein concentrate, MPC) was also 
used in a double-blind, placebo-controlled clinical tri-
al on adult patients suffering from osteoarthritis. This 
was a 6-week study having three different treatment 
protocols: MPC, glucosamine sulfate and placebo [116]. 
Osteoarthritis index scores (joint pain, joint stiffness, 
activities and total) were evaluated. The results showed 
that MPC ameliorated the symptoms of osteoarthritis as 
compared to the baseline evaluation in all scores.
Transforming growth factor beta (TGF-β) 1 and 2 are 
growth factors present in milk in low but physiological-
ly relevant concentrations (in human and bovine milk 
<1 mg/L) and have effects on several cellular process, 
such as cell proliferation and differentiation. They af-
fect T-cells, B-cells, NK-cells, dendritic cells, macropha-
ges, epithelial, endothelial and hematopoietic cells [60]. 
TGF-β2 plays an important role in maturation of imma-
ture human intestinal epithelial cells and inhibits the 
inflammatory cytokine response [83]. TGF-β in milk can 
induce and maintain oral tolerance and therefore can 
be involved in prevention of allergy [63].
Taking advantage of the property of this cytokine, a 
new product was manufactured, with casein as its pro-
tein source, enriched in milk-derived TGF-β2 (Modulen 
IBD®; Nestlé Nutrition), which found application in the 
treatment of pediatric Crohn’s disease (CD). In a ret-
rospective analysis, using this product for exclusive 
enteral feeding of children with Crohn’s disease, remis-
sion in 80% of newly diagnosed CD and 58% with long-
standing disease and improvement of nutritional status 
were registered [20]. In another study on pediatric CD 
patients fed Modulen IBD® for 8 weeks, clinical remis-
sion and improvement in the parameters characteriz-
ing inflammation of the intestinal mucosa (histologi-
cal remission) were observed [78]. Other investigators 
reviewed charts of children with CD in a retrospective 
study [34]. 28 children received Modulen IBD®, in ad-
dition to conventional treatment, as a supplement to 
their regular nutrition. These subjects were compared 
with 18 children supplemented with standard poly-
meric formula (Ensure Plus®; Abbot Laboratories) and 
18 children with standard nutrition (without formula 
supplementation). A significant decline in disease se-
verity score (clinical response) was associated with im-
provement in body mass index and inflammatory mark-
ers (erythrocyte sedimentation rate) and was observed 
only in the Modulen IBD® group. Children fed Ensure 
Plus® formula had only a decline in the disease severity 
score. In another, retrospective trial by Rubio et al. the 
8-week application of Modulen IBD® as exclusive nutri-
tional therapy, beside clinical remission of the disease 
(in 75% of orally and 85% of enterally treated patients) 
resulted in mucosal healing as evidenced in a follow-up 
endoscopy in a subgroup of patients. All patients also 
showed a significant improvement in anthropometric 
measures [85].
Mucins are another active protein component in milk 
(apart from whey proteins and caseins). Mucins speci-
fically surround milk fat globules, forming a chemical 
barrier: milk fat globule membrane proteins (MFGM). 
Mucins constitute about 1-2% of total milk proteins. Hu-
man milk mucins can bind to rotaviruses, inhibit viral 
replication and prevent experimental gastroenteritis. 
They also inhibited binding of E. coli to buccal epithe-
lial cells [62]. In a randomized, double-blind, placebo-
-controlled study with 550 infants (6-11 months old) the 
effect of MFGM-enriched protein fraction in a comple-
mentary food for 6 months was evaluated [115]. Nutri-
tional status, anthropometry and diarrhea morbidity 813
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were assessed. The consumption of the MFGM protein 
fraction reduced the incidence of diarrhea and severe 
diarrhea, its prevalence and duration and the number 
of children with persistent diarrhea as compared to the 
control infants who received skim milk proteins. This 
indicates that the addition of an MFGM fraction to the 
diet may reduce the incidence of diarrhea and improve 
health in vulnerable populations.
β-lactoglobulin (LG) is the most abundant whey 
protein in bovine milk, while it is absent in human 
milk (Fig. 1). As yet no clinical trials have been per-
formed with use of this protein or the protein-de-
rived peptides, but their activities were confirmed 
in vitro and in animal studies. LG is, among others, a 
source of peptides lowering bloodpressure via inhi-
bition of ACE. Lactokinin (142-148), β-lactosin (142-
145) and β-lactorphin (102-105) can serve as examples 
of such peptides. Conversely, β-lactotensin (146-149) 
exhibits hypertensive activity. β-lactorphin and 
β-lactotensin are also opioid receptor agonists. LG has 
also antioxidant, antitumor, antiviral and hypocholes-
terolemic effects [19,26,44,53,91] (Table 2).
conclusIons
Milk is a rich source of proteins and peptides of proven nu-
tritional and immunotropic activities. Preparation of bio-
logically active proteins and peptides usually requires en-
zymatic degradation or chemical modification or addition 
of specific cofactors. The milk-derived preparations have 
found broad application in the food industry, production of 
infant formulas, and hygiene products. The products have 
found application as preventive or therapeutic measures 
for a broad array of pathological states in neonates, infants, 
adults and the elderly, with no adverse effects. In conclu-
sion, milk-derived proteins and peptides may represent a 
supplementary treatment to conventional therapy. Many 
of these proteins and peptides have been commercialized 
as ingredients of nutraceuticals (supplements of diet and 
functional food) and hygiene products. Sour milk Calpis® 
(Calpis Co., Japan) and fermented milk Evolus® (Valio, Fin-
land) with IPP and VPP as active compounds, casein hydro-
lysate Casein DP® (Kanebo Ltd., Japan) with FFVAPFPEVFGK 
as the active compound and whey protein hydrolysate 
BioZate® (Davisco, U.S.) with whey peptides are examples 
of such commercial products [26].
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